Jiyoung Ahn Morrison

Title: Jiyoung Ahn Morrison: Innovator in Cancer Immunotherapy

Introduction

Jiyoung Ahn Morrison is a prominent inventor based in Chapel Hill, NC (US). She has made significant contributions to the field of cancer immunotherapy through her innovative research and development of advanced therapeutic techniques.

Latest Patents

Jiyoung Ahn Morrison holds a patent for "Highly modular biepitopic and bispecific CAR-T cells for cancer immunotherapy." This patent describes biepitopic or bispecific chimeric antigen receptors that utilize a combination of single domain antibody mimics. These mimics can be monobodies, affibodies, or DARPins. The chimeric antigen receptors are designed to recognize two different epitopes of the same tumor antigen, such as HER-2 or EGFR. Additionally, they may recognize two epitopes of two different tumor antigens, enhancing their effectiveness in targeting cancer cells. The application of these chimeric antigen receptors in immune cells holds promise for advancing cancer immunotherapy.

Career Highlights

Jiyoung Ahn Morrison is affiliated with the University of North Carolina at Chapel Hill, where she continues her research and development efforts. Her work focuses on creating innovative solutions to combat cancer through immunotherapy.

Collaborations

Some of her notable coworkers include Rihe Liu and Gianpietro Dotti, who contribute to her research initiatives and collaborative projects.

Conclusion

Jiyoung Ahn Morrison is a trailblazer in the field of cancer immunotherapy, with her patented innovations paving the way for new therapeutic approaches. Her work exemplifies the potential of advanced research in improving cancer treatment outcomes.